Samantha Singer
Director/Board Member bei 501 ACQU
Profil
Samantha Singer is currently the President, Chief Executive Officer & Director at Abata Therapeutics, Inc. She is also the Chairman at Institute For Protein Innovation, Inc. Additionally, she holds the position of Director at Rodin Therapeutics, Inc. and Independent Director at 5:01 Acquisition Corp.
Ms. Singer is also the Chief Operating Officer at Thrive Earlier Detection Corp.
In the past, Ms. Singer served as the Chief Operating Officer at The Broad Institute, Inc. from 2014 to 2018.
Ms. Singer completed her undergraduate studies at the University of Kansas.
She then pursued graduate studies at The Rockefeller University.
She also holds an MBA from Harvard Business School.
Aktive Positionen von Samantha Singer
| Unternehmen | Position | Beginn |
|---|---|---|
| 501 ACQU | Director/Board Member | 01.11.2020 |
Rodin Therapeutics, Inc.
 Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Director/Board Member | 21.12.2015 |
Thrive Earlier Detection Corp.
 Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Chief Operating Officer | - |
Abata Therapeutics, Inc.
 Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer. | Chief Executive Officer | 01.06.2021 |
Institute For Protein Innovation, Inc.
 Institute For Protein Innovation, Inc. Miscellaneous Commercial ServicesCommercial Services Institute For Protein Innovation, Inc. is a non-profit company that focuses on enhancing the potential of recombinant antibodies. The company is based in Boston, MA. The company uses sophisticated yeast display technology to generate synthetic, recombinant antibodies. The company was founded by Andrew Kruse, Timothy A. Springer. Kenneth Fasman has been the CEO of the company since 2022. | Chairman | 01.01.2021 |
Ehemalige bekannte Positionen von Samantha Singer
| Unternehmen | Position | Ende |
|---|---|---|
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Chief Operating Officer | 01.12.2018 |
Ausbildung von Samantha Singer
| University of Kansas | Undergraduate Degree |
| The Rockefeller University | Graduate Degree |
| Harvard Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Institute For Protein Innovation, Inc.
Institute For Protein Innovation, Inc. Miscellaneous Commercial ServicesCommercial Services Institute For Protein Innovation, Inc. is a non-profit company that focuses on enhancing the potential of recombinant antibodies. The company is based in Boston, MA. The company uses sophisticated yeast display technology to generate synthetic, recombinant antibodies. The company was founded by Andrew Kruse, Timothy A. Springer. Kenneth Fasman has been the CEO of the company since 2022. | Commercial Services |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Health Technology |
5:01 Acquisition Corp.
 5:01 Acquisition Corp. Financial ConglomeratesFinance 5:01 Acquisition Corp. is a blank check emerging growth company that was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on August 31, 2020 and is headquartered in San Francisco, CA. | Finance |
Abata Therapeutics, Inc.
Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer. | Health Technology |
